Ypsomed Holding AG/Fr. YPSN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Ypsomed Holding AG
Ypsomed Holding AG is a Swiss company specializing in the development and manufacturing of injection and infusion systems for self-medication, primarily serving the pharmaceuticals and biotechnology industries. Its key products include insulin pens, autoinjectors, infusion sets, and digital health solutions, catering to therapy areas such as diabetes management. Founded in 1984, the company is headquartered in Burgdorf, Switzerland, and operates globally with subsidiaries and distributors across Europe, North America, and Asia-Pacific regions. Ypsomed leverages its expertise in precision injection technology and its strategic partnerships with leading drug manufacturers to maintain its competitive position in the medical technology sector.
- Ticker
- Fr. YPSN
- Sector
- Health
- Primary listing
- XSWX
- Employees
- 2,025
- Headquarters
- Burgdorf, Switzerland
- Website
- www.ypsomed.com
YPSN Metrics
BasicAdvanced
CHF 5.2B
24.29
CHF 16.30
0.74
CHF 4.40
0.68%
Price and volume
Market cap
CHF 5.2B
Beta
0.74
52-week high
CHF 418.00
52-week low
CHF 260.50
Average daily volume
12K
Dividend rate
CHF 4.40
Financial strength
Current ratio
1.069
Quick ratio
0.735
Long term debt to equity
0.149
Total debt to equity
0.349
Dividend payout ratio (TTM)
13.53%
Interest coverage (TTM)
83.19%
Profitability
EBITDA (TTM)
325.791
Gross margin (TTM)
43.04%
Net profit margin (TTM)
30.36%
Operating margin (TTM)
36.20%
Effective tax rate (TTM)
7.90%
Revenue per employee (TTM)
CHF 360,000
Management effectiveness
Return on assets (TTM)
12.36%
Return on equity (TTM)
31.09%
Valuation
Price to earnings (TTM)
24.294
Price to revenue (TTM)
7.372
Price to book
6.94
Price to tangible book (TTM)
7.06
Price to free cash flow (TTM)
-329.701
Free cash flow yield (TTM)
-0.30%
Free cash flow per share (TTM)
-1.201
Dividend yield (TTM)
1.11%
Forward dividend yield
0.68%
Growth
Revenue change (TTM)
-2.39%
Earnings per share change (TTM)
154.29%
3-year revenue growth (CAGR)
13.69%
10-year revenue growth (CAGR)
8.05%
3-year earnings per share growth (CAGR)
62.20%
10-year earnings per share growth (CAGR)
19.11%
3-year dividend per share growth (CAGR)
50.14%
10-year dividend per share growth (CAGR)
15.97%
What the Analysts think about YPSN
Analyst ratings (Buy, Hold, Sell) for Ypsomed Holding AG stock.
Analyst projections of the future price of Ypsomed Holding AG stock.
Bulls say / Bears say
Delivery Systems revenue rose about 20% in FY2025/26, commercial autoinjector sales grew 33.6%, and Ypsomed won a record 44 new projects. That gives the company a strong base of current demand and future programmes. (Ypsomed)
Ypsomed forecasts 12–15% like-for-like sales growth and CHF 210–230 million of EBIT for its continuing Delivery Systems business in 2026/27. The guidance points to further growth even as the group phases out contract manufacturing. (Ypsomed)
The European Medicines Agency has qualified a bridging approach using Ypsomed’s YpsoMate devices that can avoid repeated, molecule-specific studies when some medicines move from manual injection to an autoinjector. If customers adopt it, the approach could make YpsoMate programmes quicker and less costly to develop. (Ypsomed)
A weaker clinical outlook for Novo Nordisk’s CagriSema prompted UBS to cut its Ypsomed rating, as the drug could be a meaningful source of future device demand. Barclays has also estimated that a non-launch would reduce its 2030 EBIT forecast, leaving Ypsomed exposed to the success of a major customer’s drug. (TrustFinance, Investing.com)
Ypsomed is investing heavily in new manufacturing capacity: fixed-asset investment rose to CHF 295.6 million from CHF 205.6 million. If new lines and sites are not filled or ramped up smoothly, the expansion could weigh on cash flow and margins; the company has also cited ramp-up costs and volume-based pricing effects. (Ypsomed, Simply Wall St)
The headline rise in FY2025/26 group EBIT partly reflected a one-off gain from selling the Diabetes Care business, while group revenue fell 2.4%. This makes the reported profit jump a poor guide to repeatable growth on its own. (Ypsomed)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2026.
YPSN Financial Performance
Revenues and expenses
YPSN Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing YPSN
AllUSDEURGBP
Fund name | Fund size | Fr. YPSN weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.12% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.12% |
iShares MSCI World Small Cap£WLDS | $9B | 0.02% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
iShares MSCI World Small Cap€IUSN | $9B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.